Elena Hawryluk MD PhD

Elena Hawryluk, MD, PhD

Attending Physician, Dermatology

Assistant Professor of Dermatology, Harvard Medical School

    Contact: 617-355-6117
  • Fax: 617-730-0308

Medical Services


  • Dermatology Program


  • English


  • Dermatology Program
To schedule an appointment: Call 617-355-6117 or Request an Appointment

Experience and Education


Medical School, MD, PhD

University of Pittsburgh School of Medicine, 2009


St. Vincent Hospital,

Worcester, MA

Residency, Dermatology

Harvard Medical School Combined Dermatology Residency Program, 2010-2013

Boston, MA


Boston Children's Hospital, Harvard Medical School, 2013-2014


  • American Board of Dermatology

  • American Board of Dermatology


Publications powered by Harvard Catalyst Profiles
  1. McCORMACK L, Hawryluk EB. Pediatric melanoma update. G Ital Dermatol Venereol. 2018 Feb 26.
  2. Gordon SC, Bartenstein DW, Tajmir SH, Song JS, Hawryluk EB. Delayed-type hypersensitivity to vaccine aluminum adjuvant causing subcutaneous leg mass and urticaria in a child. Pediatr Dermatol. 2018 Jan 04.
  3. Song JS, London WB, Hawryluk EB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN, Huang JT. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Jul; 52(7):989-997.
  4. Bartenstein DW, Song JS, Nazarian RM, Hawryluk EB. Evolving Childhood Melanoma Monitored by Parental Photodocumentation. J Pediatr. 2017 Jul; 186:205-205.e1.
  5. Song H, Song JS, Merola MC, Nazarian RM, Hawryluk EB. Pigmented purpuric dermatosis: a striking but benign cutaneous entity. Arch Dis Child. 2017 Dec; 102(12):1157.
  6. LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, Rea C, Lee M, Schneider LC. Multidisciplinary interventions in the management of atopic dermatitis. J Allergy Clin Immunol. 2016 Aug; 138(2):325-34.
  7. Hawryluk EB, Schmidt B, Maguiness S. Enlargement of eccrine angiomatous hamartoma following trauma. Pediatr Dermatol. 2015 May-Jun; 32(3):e92-4.
  8. Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: a retrospective review. J Am Acad Dermatol. 2015 Feb; 72(2):314-20.
  9. Sheu J, Hawryluk EB, Litsas G, Thakuria M, LeBoeuf NR. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor. Clin Breast Cancer. 2015 Feb; 15(1):e77-81.
  10. Hawryluk EB, Tsao H. Melanoma: clinical features and genomic insights. Cold Spring Harb Perspect Med. 2014 Sep 02; 4(9):a015388.
  11. Show all
  12. Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol. 2014 Mar; 150(3):307-11.
  13. Hawryluk EB, Liang MG. Pediatric melanoma, moles, and sun safety. Pediatr Clin North Am. 2014 Apr; 61(2):279-91.
  14. Alloo A, Strazzula L, Rothschild B, Hawryluk E, Levine D, Hoang MP, Koga H, Hashimoto T, Kroshinsky D. Refractory antilaminin ?1 pemphigoid successfully treated with intravenous immunoglobulin and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2014 Oct; 28(10):1401-3.
  15. Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4321-6.
  16. Hawryluk EB, Baran JL, Gerami P, Sepehr A. 'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification. J Cutan Pathol. 2013 Jan; 40(1):61-5.
  17. Hawryluk EB, O'Regan KN, Sheehy N, Guo Y, Dorosario A, Sakellis CG, Jacene HA, Wang LC. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-9.
  18. Hanash AM, Dudakov JA, Hua G, O'Connor MH, Young LF, Singer NV, West ML, Jenq RR, Holland AM, Kappel LW, Ghosh A, Tsai JJ, Rao UK, Yim NL, Smith OM, Velardi E, Hawryluk EB, Murphy GF, Liu C, Fouser LA, Kolesnick R, Blazar BR, van den Brink MR. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012 Aug 24; 37(2):339-50.
  19. Sheikine Y, Hawryluk EB, Burgin S, Zimarowski MJ. Histopathology of measles exanthem: a case with characteristic features and eosinophils. J Cutan Pathol. 2012 Jul; 39(7):667-70.
  20. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012 May; 39(5):481-92.
  21. Hawryluk EB, Sober AJ, Piris A, Nazarian RM, Hoang MP, Tsao H, Mihm MC, Duncan LM. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol. 2012 Oct; 67(4):727-35.
  22. Ko J, Hawryluk E, Taylor CR. Part II: high-yield dermatologic signs the Harvard combined program in dermatology. J Drugs Dermatol. 2011 Feb; 10(2):197-8.
  23. Hawryluk EB, Penn SK, Wasko MC, Johnson JT, Ferris LK. Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid. Ear Nose Throat J. 2010 Jun; 89(6):E5-7.
  24. Hawryluk EB, Izikson L, English JC. Non-infectious granulomatous diseases of the skin and their associated systemic diseases: an evidence-based update to important clinical questions. Am J Clin Dermatol. 2010; 11(3):171-81.
  25. Hawryluk EB, English JC. Female adolescent hair disorders. J Pediatr Adolesc Gynecol. 2009 Aug; 22(4):271-81.
  26. Spencer LA, Hawryluk EB, English JC. Lichen planopilaris: retrospective study and stepwise therapeutic approach. Arch Dermatol. 2009 Mar; 145(3):333-4.
  27. Khandelwal P, Ruiz WG, Balestreire-Hawryluk E, Weisz OA, Goldenring JR, Apodaca G. Rab11a-dependent exocytosis of discoidal/fusiform vesicles in bladder umbrella cells. Proc Natl Acad Sci U S A. 2008 Oct 14; 105(41):15773-8.
  28. Studeny S, Cheppudira BP, Meyers S, Balestreire EM, Apodaca G, Birder LA, Braas KM, Waschek JA, May V, Vizzard MA. Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice. J Mol Neurosci. 2008 Nov; 36(1-3):175-87.
  29. Balestreire E, Haught JM, English JC. Multiple subcutaneous lipomas induced by HAART in the absence of protease inhibitors. Arch Dermatol. 2007 Dec; 143(12):1596-7.
  30. Apodaca G, Balestreire E, Birder LA. The uroepithelial-associated sensory web. Kidney Int. 2007 Nov; 72(9):1057-64.
  31. Balestreire EM, Apodaca G. Apical epidermal growth factor receptor signaling: regulation of stretch-dependent exocytosis in bladder umbrella cells. Mol Biol Cell. 2007 Apr; 18(4):1312-23.
  32. Wang EC, Lee JM, Ruiz WG, Balestreire EM, von Bodungen M, Barrick S, Cockayne DA, Birder LA, Apodaca G. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest. 2005 Sep; 115(9):2412-22.
  33. Rhodes ME, Balestreire EM, Czambel RK, Rubin RT. Estrous cycle influences on sexual diergism of HPA axis responses to cholinergic stimulation in rats. Brain Res Bull. 2002 Nov 30; 59(3):217-25.
To schedule an appointment: Call 617-355-6117 or Request an Appointment


Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337